• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Gyre Therapeutics Inc.

    9/6/24 8:31:07 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GYRE alert in real time by email
    SC 13D 1 ef20035609_sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*


    Gyre Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    403783 103
    (CUSIP Number)
     
    12770 High Bluff Drive, Suite 150
     San Diego, California, 92130
    (858) 567-7770
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
    September 6, 2024
    (Date of Event Which Requires Filing of this Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 403783 103

    1
    NAMES OF REPORTING PERSONS
     
     
    Songjiang Ma (“Mr. Ma”)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    People’s Republic of China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    7,456,847
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    7,456,847
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    7,456,847(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.62%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1)
    Represents (i) 4,514,380 shares underlying the options directly held by Mr. Ma that are exercisable within 60 days after the date hereof and (ii) 2,942,467 shares directly held by Yueying Zhu (“Ms. Zhu”), the spouse of Mr. Ma.
    (2)
    All percentage calculations herein are based on 97,938,564 shares of common stock, consisting of (i) 93,424,184 shares of common stock outstanding as of August 6, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024 (the “Form 10-Q”) and (ii) 4,514,380 shares underlying the options directly held by Mr. Ma that are exercisable within 60 days after the date hereof.


    CUSIP No. 403783 103

    1
    NAMES OF REPORTING PERSONS
     
     
    Yueying Zhu
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    7,456,847
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    7,456,847
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    7,456,847(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.62%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1)
    Represents (i) 2,942,467 shares directly held by Ms. Zhu and (ii) 4,514,380 shares underlying the options directly held by Mr. Ma that are exercisable within 60 days after the date hereof.
    (2)
    All percentage calculations herein are based on 97,938,564 shares of common stock, consisting of (i) 93,424,184 shares of common stock outstanding as of August 6, 2024, as disclosed in the Form 10-Q and (ii) 4,514,380 shares underlying the options directly held by Mr. Ma that are exercisable within 60 days after the date hereof


    CUSIP No. 403783 103

    Item 1.
    Security and Issuer.
     
    This statement on Schedule 13D (the “Schedule 13D”) relates to the common stock, par value $0.001 per share (the “Common Stock”), of Gyre Therapeutics, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive office is 12770 High Bluff Drive Suite 150, San Diego, California, 92130.

    Item 2.
    Identity and Background

      (a)
    This Schedule 13D is being jointly filed by Mr. Ma and Ms. Zhu (each, a “Reporting Person” and collectively, the “Reporting Persons”).


    (b)
    The business address of the Reporting Persons is c/o Beijing Continent Pharmaceuticals Co., Ltd, at 6th floor, Junkang Life Insurance Building, No.1 Building, Wangjing Dongyuan 4 District, Chaoyang District, Beijing, People’s Republic of China.


    (c)
    The principal occupation of Mr. Ma is the President and a director of the Issuer. Ms. Zhu does not have an occupation.


    (d)
    Neither of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     

    (e)
    Neither of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     

    (f)
    Mr. Ma is a citizen of the People’s Republic of China. Ms. Zhu is a citizen of Canada.

    The Reporting Persons have executed a Joint Filing Agreement, dated September 6, 2024, with respect to the joint filing of this Schedule 13D, and any amendment or amendments hereto, a copy of which is attached hereto as Exhibit 1.

    Item 3.
    Source and Amount of Funds or Other Consideration.

    Upon the consummation of a business combination among the Issuer and certain other parties on October 30, 2023, Ms. Zhu acquired 2,942,467 shares of Common Stock (after taking into account a 1-for-15 reverse stock split of the Issuer’s common stock on October 30, 2023) in consideration of her contribution of certain indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd (“Beijing Continent”), a company organized under the laws of the People’s Republic of China, to the Issuer pursuant to the terms of the business combination.

    On October 30, 2023, Beijing Continent terminated its 2021 Stock Incentive Plan and all outstanding options thereunder as part of the business combination arrangement. As a replacement of the terminated options, the Issuer granted options to purchase 4,510,047 shares of Common Stock to Mr. Ma under a subplan for Chinese participants under the Issuer’s 2023 Omnibus Incentive Plan. These options are vested in full.

    On August 14, 2024, the Issuer granted Mr. Ma an option to purchase a total of 26,000 shares of Common Stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to Mr. Ma’s continued service to the Issuer or its affiliates through each vesting date.


    Item 4.
    Purpose of Transaction
     
    The shares of Common Stock held by the Reporting Persons are held for investment purposes. The Reporting Persons have no present plans or proposals relating to or that would result in any of the events or consequences referred to in paragraphs (a) through (j) of this Item 4 of Schedule 13D. The Reporting Persons may from time to time acquire or dispose of their shares, including acquisitions through the exercise of stock options. Among other considerations, the timing and amount of additional purchases or dispositions will be subject to market conditions, the price at which Common Stock can be purchased, and the Reporting Persons’ personal finances.

    Item 5.
    Interest in Securities of the Issuer

    (a)-(b)
    The responses of the Reporting Persons to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Schedule 13D are incorporated herein by reference. The Reporting Persons currently beneficially own an aggregate of 7,456,847 shares of Common Stock, or 7.62% of the shares of Common Stock of the Issuer. The foregoing amount of Common Stock and percentage ownership represent the combined beneficial ownership of Mr. Ma and Ms. Zhu. The Reporting Persons share the power to vote or direct the vote and dispose of or direct the disposition of the shares of Common Stock referred to in this Schedule 13D.
     
    (c)
    Except as set forth in this Schedule 13D, no Reporting Person has effected any transaction in the Common Stock in the 60 days preceding the date hereof.
     
    (d)
    None.
     
    (e)
    Not applicable.
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
     
    Other than as described in this Schedule 13D, there are no contracts, arrangements, understandings, plans, or proposals to which any Reporting Person is a party that have to do with the Issuer or its securities, other than stock option agreements entered into by the Issuer and such Reporting Person for stock options granted under the Issuer’s stock option plans.

    Item 7.
    Materials to be Filed as Exhibits

    Exhibit
    Number
    Description
       
    1
    Joint Filing Agreement dated September 6, 2024, between the Reporting Persons.


    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date: September 6, 2024

    /s/ Songjiang Ma
    SONGJIANG MA
     
    /s/ Yueying Zhu
    YUEYING ZHU



    Get the next $GYRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GYRE

    DatePrice TargetRatingAnalyst
    3/11/2025Outperform
    Noble Capital Markets
    More analyst ratings

    $GYRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

      SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to Gyre, before deducting the underwriting discounts and commissions and other of

      5/22/25 8:57:29 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

      SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Gyre is expected to grant the underwriters of the offering an option for a period of 30 days to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the

      5/22/25 4:02:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

      Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to adverse events.Breakthrough Therapy Designation granted by China's National Medical Products Administration ("NMPA") in 2021 supports potential first-in-class approval in CHB-associated liver fibrosis ("CHB fibrosis").Gyre intends to seek accelerated approval for Hydronidone in CHB fibrosis, with a New Drug Application ("NDA") submission to the NMPA expected in Q3 2025. U.S. Phase 2 trial in MASH-associated liver fibrosis expected to begin in

      5/22/25 4:01:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:31:07 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:15:45 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

      1/6/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

      SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of Directors and as a member of its Audit Committee. "Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forwa

      3/21/24 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Gyre Therapeutics

      Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform

      3/11/25 10:02:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Financials

    Live finance-specific insights

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

      3/17/25 4:15:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

      11/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ma Songjiang sold $44,160 worth of shares (4,000 units at $11.04) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/22/25 4:01:08 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $44,840 worth of shares (4,000 units at $11.21) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/20/25 4:01:17 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $21,586 worth of shares (2,020 units at $10.69) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      5/16/25 4:01:12 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GYRE
    SEC Filings

    See more
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/23/25 4:46:36 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Gyre Therapeutics Inc.

      424B5 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/23/25 4:37:26 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Gyre Therapeutics Inc.

      424B5 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/22/25 5:27:39 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care